{"prompt": "['Novartis', 'Confidential', 'Page 14', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'significant asthma worsening as defined by Investigator within 4', 'weeks prior to Visit 1 or between Visit 1 and Visit 201.', 'Study treatment', 'QVM149 (indacaterol acetate/glycopyronium bromide/MF)', 'Open label salmeterol xinafoate /fluticasone propionate +', 'tiotropium', 'Efficacy assessments', 'Health Status (PROs: AQLQ, ACQ-7,', 'Spirometry', 'Key safety', 'Medical history and physical examination', 'assessments', 'Vital signs', 'Labs: Hematology, Blood chemistry, Urinalysis', 'ECG', 'Adverse events (AE) including serious adverse events (SAE)', 'Pregnancy (female patients)', 'Serious asthma outcomes (asthma-related hospitalizations,', 'intubations or deaths)', 'CCV (Cardiovascular and cerebrovascular) events and new onset', 'of atrial fibrillation', 'Other assessments', 'Data analysis', 'Analysis of primary variable', 'The non-inferiority of QVM149 150/50/160 g o.d. versus free', 'combination of salmeterol/ fluticasone 50/500 g + tiotropium 5 g', 'and QVM149 150/50/80 g o.d. versus free combination of', 'salmeterol/ fluticasone 50/500 g + tiotropium 5 g, in terms of', 'change from baseline in AQLQ total score.', 'The primary variable will be analyzed using a mixed model for', 'repeated measure (MMRM) on the full analysis set (FAS).', 'Key words', 'QVM149, Asthma']['Novartis', 'Confidential', 'Page 15', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '1 Introduction', '1.1 Background', 'Asthma is a chronic inflammatory disorder of the airways associated with airways hyper', 'responsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness,', 'and coughing, particularly at night or in the early morning. These episodes are usually', 'associated with widespread but variable airflow obstruction that is often reversible either', 'spontaneously or with treatment. Airflow limitation occurs as a result of obstruction or', 'narrowing of the airways, when exposed to precipitating factors. Exacerbations of asthma are', 'episodic whereas inflammation is chronic (GINA 2017).', 'Despite existing therapies there are still significant unmet medical needs in asthma, with an', 'estimated 300 million people affected worldwide. The Global Burden of Asthma Report', 'estimates that 15 million disability-adjusted life years (DALYs) are lost annually due to', 'asthma, representing 1% of the total global burden. Annual worldwide deaths have been', 'estimated at 250,000 (Masoli, 2004).', 'Many patients with asthma fail to achieve adequate control of symptoms and exacerbations', 'when treated with inhaled corticosteroids (ICS) or combinations of ICS and long-acting beta-', 'agonists (LABA). Failure to respond to inhaled therapy may be due to multiple factors,', 'including poor adherence, inadequate inhaler technique or corticosteroid resistance.', 'Tiotropium (SpirivaR Respimat\u00ae) has been approved in European Union (EU) as an add-on', 'maintenance bronchodilator treatment in adult patients (> 18 years) with asthma who are', 'currently treated with the maintenance combination of inhaled corticosteroids @> 800g', 'budesonide/day or equivalent) and long-acting \u00df2-agonists and who experienced one or more', 'severe exacerbations in the previous year.', 'Following tiotropium regulatory approval in asthma, GINA guideline (2017) recommends', 'tiotropium as a new add-on option on top of ICS/LABA for steps 4 and 5 in patients with a', 'history of exacerbations (in step 4 in the list of other controller options and in step 5 in the list', 'of preferred controller choices).', 'QVM149 is a fixed-dose combination of indacaterol acetate (inhaled LABA with 24 hour', 'duration of action), glycopyrronium bromide (inhaled LAMA with 24 hours duration of', 'action), and mometasone furoate (MF, ICS with 24 hour duration of action) in development', 'for once-daily maintenance treatment of asthma GINA step > 4. All three mono-components', 'have previously been developed as individual drugs for either COPD (indacaterol maleate and', 'glycopyrronium bromide) or Asthma (mometasone furoate). Novartis is developing QVM149', '(LABA/LAMA/ICS) fixed dose combination (FDC) as a lactose-blended inhalation powder to', 'be delivered via Conceptl (Breezhaler\u00ae), a single dose dry powder inhaler (SDDPI) for', 'maintenance treatment for severe asthma (GINA 2017 Step > 4).', 'Data from mono-components:', 'QVM149 is being developed in parallel with QMF149 (indacaterol acetate/mometasone', 'furoate). Existing efficacy and safety data for the three mono-components', 'indacaterol/mometasone/glycopyironium) of the QVM149 FDC as well as for the two']\n\n###\n\n", "completion": "END"}